Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

Summary

The primary goal of the study is to assess the efficacy and safety of RPH-104 in subjects with Schnitzler Syndrome using Schnitzler Disease Activity Score (SDAS), which includes the Physician's Global Assessment (PGA) and the local laboratory C-reactive protein (CRP) result

Timeline

Start

2023-05

Primary completion

2023-08

Completion

2024-01

Drugs

Indications